(BVII) (BVII) Stock Price, News & Analysis

Company Overview

BioVision II, Inc. is a clinical-stage biotechnology company focused on the development of innovative gene therapies for rare and orphan diseases. The company’s research pipeline leverages proprietary viral vector platforms and precision genome-editing technologies to address high-unmet medical needs in neuromuscular, retinal and metabolic disorders. Lead programs are advancing through preclinical and early-phase clinical studies in the United States and Europe.

Founded in 2006 as a spin-out from a leading academic research center, BioVision II has forged strategic collaborations and licensing agreements with major pharmaceutical and biotechnology partners. Its core technology emphasizes enhanced tissue targeting and durable gene expression, designed to maximize therapeutic benefit while minimizing off-target effects. This approach has positioned BioVision II as a notable contender in the competitive gene therapy landscape.

The company operates research and manufacturing facilities in Boston, Massachusetts and Heidelberg, Germany, supporting vector production, process development and in vivo testing. BioVision II is led by Chief Executive Officer Dr. Laura Fernández, a seasoned leader in translational research, and Executive Chairman Michael Thompson, who has extensive experience in life science corporate strategy and capital markets. Together, they have guided the company through multiple financing rounds and regulatory achievements, including successful IND submissions.

In addition to its proprietary pipeline, BioVision II offers contract research services to academic institutions and emerging biotech firms, encompassing vector manufacturing, analytical characterization and regulatory support. These services generate supplementary revenue while fostering collaborative research that extends the reach of its core platforms. With a dual focus on scientific innovation and strategic partnerships, BioVision II remains committed to delivering transformative therapies to patients with rare genetic conditions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 3,442 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVII Stock Analysis - Frequently Asked Questions

How do I buy shares of (BVII)?

Shares of BVII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Electronic Computer Manufacturing
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:BVII
• CIK: 73048
• Web: www.broadviewinstitute.com
• Phone: +1-651-3328000
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A